HYDROCORTONE Drug Patent Profile

Which patents cover Hydrocortone, and when can generic versions of Hydrocortone launch?

Hydrocortone is a drug marketed by Merck and is included in four NDAs.

The generic ingredient in HYDROCORTONE is hydrocortisone. There are sixty-seven drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the hydrocortisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hydrocortone

A generic version of HYDROCORTONE was approved as hydrocortisone by IMPAX LABS INC on March 30^th, 2007.

Summary for HYDROCORTONE

US Patents:	0
Applicants:	1
NDAs:	4
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	13
DailyMed Link:	HYDROCORTONE at DailyMed

Recent Clinical Trials for HYDROCORTONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 1
Children's Oncology Group	Phase 1
EsPhALL network I-BFM Study Group	Phase 3

See all HYDROCORTONE clinical trials

US Patents and Regulatory Information for HYDROCORTONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	HYDROCORTONE	hydrocortisone acetate	INJECTABLE;INJECTION	008228-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Merck	HYDROCORTONE	hydrocortisone acetate	OINTMENT;OPHTHALMIC, OTIC	009018-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Merck	HYDROCORTONE	hydrocortisone acetate	INJECTABLE;INJECTION	008228-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Merck	HYDROCORTONE	hydrocortisone sodium phosphate	INJECTABLE;INJECTION	012052-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	HYDROCORTONE	hydrocortisone	TABLET;ORAL	008506-011	Approved Prior to Jan 1, 1982		DISCN	No	No
Merck	HYDROCORTONE	hydrocortisone	TABLET;ORAL	008506-007	Approved Prior to Jan 1, 1982		DISCN	No	No

EU/EMA Drug Approvals for HYDROCORTONE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch	Plenadren	hydrocortisone	EMEA/H/C/002185Treatment of adrenal insufficiency in adults.	Authorised	no	no	no	2011-11-03
Diurnal Europe B.V.	Alkindi	hydrocortisone	EMEA/H/C/004416Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old).	Authorised	no	no	no	2018-02-09
Diurnal Europe B.V.	Efmody	hydrocortisone	EMEA/H/C/005105Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.	Authorised	no	no	no	2021-05-27

HYDROCORTONE Market Analysis and Financial Projection

Last updated: February 17, 2026

What Are the Market Dynamics for Hydrocortisone?

Hydrocortisone, a corticosteroid used primarily for its anti-inflammatory and immunosuppressive effects, faces a complex market landscape shaped by regulatory, competitive, and demand factors.

Market Size and Growth Trends

The global hydrocortisone market was valued at approximately $300 million in 2022 and is projected to grow at a CAGR of around 4.5% through 2027. The growth is driven by increased demand in autoimmune disorders, adrenal insufficiency, and allergic conditions.

Key End-Use Segments

• Prescription dermatology accounts for roughly 50% of sales, primarily for eczema and dermatitis.
• Endocrinology treatments for adrenal insufficiency constitute approximately 30%.
• Other applications, such as allergic and inflammatory conditions, make up the remaining market share.

Geographic Distribution

North America leads the market with about 45% market share, driven by established healthcare infrastructure, and high prevalence of autoimmune diseases. Europe accounts for nearly 30%, with steady growth in emerging markets such as Asia-Pacific, projected to grow faster owing to expanding healthcare access and increasing disease prevalence.

Competitive Landscape

Major providers include Pfizer, Teva, Mylan, and Sun Pharmaceutical. Patent expiration for several formulations has increased the availability of generic hydrocortisone, intensifying price competition.

Regulatory Environment

Hydrocortisone formulations, particularly generics, face regulatory approvals focusing on bioequivalence, safety, and manufacturing standards. Variations in approvals and quality standards across regions influence market entry and pricing.

Pricing Dynamics

Brand-name products typically sell at a premium of 20-30% over generics. The rise of biosimilars (though hydrocortisone is small molecule-based) is not prominent but could influence future pricing. Price erosion due to generic competition has been observed, with median prices decreasing about 5-7% annually in mature markets.

What Is the Financial Trajectory of Hydrocortisone?

Revenue Projections

Global revenues are forecasted to increase modestly, reaching approximately $375 million by 2027, assuming stable demand and continued generic competition.

Patent and Patent Expiry Impact

Patents on branded formulations expired in 2017-2019 in the US and Europe, leading to a proliferation of generics. Market share has shifted substantially towards generics, which now constitute over 80% of sales.

Profitability Trends

Margins for branded products were historically above 50%, but incident patent expirations reduced margins to around 25-30%. Generic producers operate with thin margins (~10-15%) but compensate through high volume sales.

Supply Chain Considerations

Manufacturing for hydrocortisone involves complex sterile and non-sterile processes. Supply chain disruptions, such as raw material shortages (notably corticosterone and related intermediates), can impact pricing and availability.

Investment Outlook

Stable demand in chronic conditions presents opportunities for formulations with improved delivery systems (e.g., topical gels and sustained-release injectables). R&D investments focus on novel formulations to differentiate from low-cost generics.

How Do External Factors Influence Market and Financial Outlook?

• Regulatory changes: Accelerated approvals for biosimilars or new formulations could reconfigure the competitive landscape.
• Healthcare policies: Price control initiatives in Europe and emerging markets could limit revenue growth.
• Patent litigation: Legal disputes over formulations or manufacturing processes could delay generic entry or influence market share.
• Emerging competitors: New corticosteroids with improved profiles might challenge hydrocortisone’s market position.

Summary Table: Market and Financial Highlights

Metric	Value / Projection
2022 Market Size	$300 million
CAGR (2023-2027)	4.5%
2027 Market Size	~$375 million
Market Share (North America)	45%
Market Share (Europe)	30%
Leading Companies	Pfizer, Teva, Mylan, Sun Pharma
Patent Expiry (US & Europe)	2017-2019
Generic Market Share	80%+
Revenue Margin (Branded)	>50% (pre-patent expiry)
Revenue Margin (Generics)	10-15%

Key Takeaways

• Market growth is modest but stable, driven by demand for essential corticosteroid treatments.
• Generic erosion has significantly impacted margins and revenue potential for branded formulations.
• Geographic disparities exist, with North America leading; emerging markets are vital for future growth.
• Regulatory, legal, and supply chain factors influence market dynamics and profitability.
• Innovation in formulation delivery presents opportunities for differentiation amid intense price competition.

FAQs

1. How does patent expiration affect hydrocortisone's market?
Patent expirations around 2017-2019 led to increased generic competition, reducing prices and margins for branded products while expanding access and volume through generics.

2. What are the main clinical uses of hydrocortisone?
They include treatment of adrenal insufficiency, allergic and inflammatory conditions, and dermatological disorders like eczema.

3. Which regions offer the highest market potential?
North America maintains the largest market share. Asia-Pacific is emerging rapidly due to expanding healthcare infrastructure and higher disease prevalence.

4. What are future growth drivers for hydrocortisone?
Development of novel formulations, such as sustained-release and topical gels, and strategic market expansion into emerging economies.

5. How is the competitive landscape evolving?
The shift toward generics diminishes profit margins for branded drugs. Firms focus on formulation innovation, cost reduction, and entering emerging markets to sustain revenue streams.